Remote video URL
Your peers rated this 5 stars
10-minute watch | Talk 3 of 4

EHA: Follow the patient pathway to survival in 2L DLBCL

Delivering CAR T

Dr Pierre Sesques
Lyon University Hospital, Lyon, France

Dr Pierre Sesques of the Lyon University Hospital, Lyon, France summarises the typical CAR T journey, emphasising the value of referral–treatment centre collaboration

Read more

Talks in this series

23-minute watch | Talk 1 of 4
EHA: Follow the patient pathway to survival in 2L DLBCL
23-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL

Planning ahead for 2L

10-minute watch | Talk 3 of 4
23-minute watch | Talk 1 of 4
EHA: Follow the patient pathway to survival in 2L DLBCL
23-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL

Planning ahead for 2L

Interested in this topic?

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.